Trial reportJournal of lipid research2011
Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus.
Trial report in Journal of lipid research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00395148 (A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Two-week step-reduction has limited negative effects on physical function and metabolic health in older adults.European journal of applied physiology · 2024Trial
- HDL and Therapy.Advances in experimental medicine and biology · 2022Article
- Diabetes Mellitus and Periodontitis Share Intracellular Disorders as the Main Meeting Point.Cells · 2021Review
- A short peptide of the C-terminal class Y helices of apolipoprotein A-I has preserved functions in cholesterol efflux and in vivo metabolic control.Scientific reports · 2020Article
- Apolipoprotein A-I Supports MSCs Survival under Stress Conditions.International journal of molecular sciences · 2020Article
- Review
- Inhibition of Triggering Receptor Expressed on Myeloid Cells 1 Ameliorates Inflammation and Macrophage and Neutrophil Activation in Alcoholic Liver Disease in Mice.Hepatology communications · 2019Article
- Lipid Profiling of In Vitro Cell Models of Adipogenic Differentiation: Relationships With Mouse Adipose Tissues.Journal of cellular biochemistry · 2016Article
- Nanomedicines for Endothelial Disorders.Nano today · 2015Article
- Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans.Diabetes care · 2015Article
- Lipidomics to Assess Omega 3 Bioactivity.Journal of clinical medicine · 2015Review
- It's Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation.Journal of the American Heart Association · 2015Article
- Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL.Biochimica et biophysica acta · 2015Article
- High-density lipoprotein: a novel target for antirestenosis therapy.Clinical and translational science · 2014Review
- Role of HDL in those with diabetes.Current cardiology reports · 2014Review
- HDL-targeted therapies: progress, failures and future.Nature reviews. Drug discovery · 2014Review
- Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.Journal of medicinal chemistry · 2014Review
- Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics.ACS nano · 2013Article
- Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes.PloS one · 2013Article
- Novel biological functions of high-density lipoprotein cholesterol.Circulation research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We recently demonstrated that reconstituted high-density lipoprotein (rHDL) modulates glucose metabolism in humans via both AMP-activated protein kinase (AMPK) in muscle and by increasing plasma insulin. Given the key roles of both AMPK and insulin in fatty acid metabolism, the current study investigated the effect of rHDL infusion on fatty acid oxidation and lipolysis. Thirteen patients with type 2 diabetes received separate infusions of rHDL and placebo in a randomized, cross-over study. Fatty acid metabolism was assessed using steady-state tracer methodology, and plasma lipids were measured by mass spectrometry (lipidomics). In vitro studies were undertaken in 3T3-L1 adipocytes. rHDL infusion inhibited fasting-induced lipolysis (P = 0.03), fatty acid oxidation (P < 0.01), and circulating glycerol (P = 0.04). In vitro, HDL inhibited adipocyte lipolysis in part via activation of AMPK, providing a possible mechanistic link for the apparent reductions in lipolysis observed in vivo. In contrast, circulating NEFA increased after rHDL infusion (P < 0.01). Lipidomic analyses implicated phospholipase hydrolysis of rHDL-associated phosphatidylcholine as the cause, rather than lipolysis of endogenous fat stores. rHDL infusion inhibits fasting-induced lipolysis and oxidation in patients with type 2 diabetes, potentially through both AMPK activation in adipose tissue and elevation of plasma insulin. The phospholipid component of rHDL also has the potentially undesirable effect of increasing circulating NEFA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.